0000805928December 312022Q3falsehttp://www.axogeninc.com/20220930#LeaseLiabilityCurrenthttp://www.axogeninc.com/20220930#LeaseLiabilityCurrenthttp://www.axogeninc.com/20220930#LeaseLiabilityNoncurrenthttp://www.axogeninc.com/20220930#LeaseLiabilityNoncurrenthttp://www.axogeninc.com/20220930#LeaseLiabilityCurrenthttp://www.axogeninc.com/20220930#LeaseLiabilityCurrenthttp://www.axogeninc.com/20220930#LeaseLiabilityNoncurrenthttp://www.axogeninc.com/20220930#LeaseLiabilityNoncurrent00008059282022-01-012022-09-3000008059282022-11-01xbrli:shares00008059282022-09-30iso4217:USD00008059282021-12-31iso4217:USDxbrli:shares00008059282022-07-012022-09-3000008059282021-07-012021-09-3000008059282021-01-012021-09-3000008059282020-12-3100008059282021-09-300000805928us-gaap:CommonStockMember2022-06-300000805928us-gaap:AdditionalPaidInCapitalMember2022-06-300000805928us-gaap:RetainedEarningsMember2022-06-3000008059282022-06-300000805928us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000805928us-gaap:CommonStockMember2022-07-012022-09-300000805928us-gaap:CommonStockMember2022-09-300000805928us-gaap:AdditionalPaidInCapitalMember2022-09-300000805928us-gaap:RetainedEarningsMember2022-09-300000805928us-gaap:CommonStockMember2021-12-310000805928us-gaap:AdditionalPaidInCapitalMember2021-12-310000805928us-gaap:RetainedEarningsMember2021-12-310000805928us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300000805928us-gaap:CommonStockMember2022-01-012022-09-300000805928us-gaap:CommonStockMember2021-06-300000805928us-gaap:AdditionalPaidInCapitalMember2021-06-300000805928us-gaap:RetainedEarningsMember2021-06-3000008059282021-06-300000805928us-gaap:RetainedEarningsMember2021-07-012021-09-300000805928us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000805928us-gaap:CommonStockMember2021-07-012021-09-300000805928us-gaap:CommonStockMember2021-09-300000805928us-gaap:AdditionalPaidInCapitalMember2021-09-300000805928us-gaap:RetainedEarningsMember2021-09-300000805928us-gaap:CommonStockMember2020-12-310000805928us-gaap:AdditionalPaidInCapitalMember2020-12-310000805928us-gaap:RetainedEarningsMember2020-12-310000805928us-gaap:RetainedEarningsMember2021-01-012021-09-300000805928us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300000805928us-gaap:CommonStockMember2021-01-012021-09-300000805928axgn:RestrictedCashMember2022-09-300000805928axgn:RestrictedCashMember2021-12-31axgn:letterOfCredit0000805928us-gaap:ShippingAndHandlingMember2022-07-012022-09-300000805928us-gaap:ShippingAndHandlingMember2021-07-012021-09-300000805928us-gaap:ShippingAndHandlingMember2022-01-012022-09-300000805928us-gaap:ShippingAndHandlingMember2021-01-012021-09-300000805928axgn:AviveMember2021-01-012021-09-300000805928axgn:FurnitureAndOfficeEquipmentMember2022-09-300000805928axgn:FurnitureAndOfficeEquipmentMember2021-12-310000805928us-gaap:LeaseholdImprovementsMember2022-09-300000805928us-gaap:LeaseholdImprovementsMember2021-12-310000805928us-gaap:EquipmentMember2022-09-300000805928us-gaap:EquipmentMember2021-12-310000805928us-gaap:LandMember2022-09-300000805928us-gaap:LandMember2021-12-310000805928us-gaap:ConstructionInProgressMember2022-09-300000805928us-gaap:ConstructionInProgressMember2021-12-310000805928us-gaap:PatentsMember2022-09-300000805928us-gaap:PatentsMember2021-12-310000805928us-gaap:LicensingAgreementsMember2022-09-300000805928us-gaap:LicensingAgreementsMember2021-12-310000805928us-gaap:TrademarksMember2022-09-300000805928us-gaap:TrademarksMember2021-12-310000805928axgn:PatentsAndLicenseAgreementsMember2022-09-300000805928us-gaap:SellingAndMarketingExpenseMember2022-07-012022-09-300000805928us-gaap:SellingAndMarketingExpenseMember2021-07-012021-09-300000805928us-gaap:SellingAndMarketingExpenseMember2022-01-012022-09-300000805928us-gaap:SellingAndMarketingExpenseMember2021-01-012021-09-300000805928axgn:OberlandFacilityMemberaxgn:DebtDerivativeLiabilityMember2022-09-30axgn:settlementScenario0000805928axgn:OberlandFacilityMemberaxgn:PeriodOneMemberaxgn:DebtDerivativeLiabilityMember2022-09-30xbrli:pure0000805928axgn:PeriodTwoMemberaxgn:OberlandFacilityMemberaxgn:DebtDerivativeLiabilityMember2022-09-300000805928axgn:PeriodThreeMemberus-gaap:StockOptionMemberaxgn:OberlandFacilityMemberaxgn:DebtDerivativeLiabilityMember2022-09-300000805928axgn:PeriodFourMemberaxgn:OberlandFacilityMemberaxgn:DebtDerivativeLiabilityMember2022-09-300000805928us-gaap:MeasurementInputExpectedTermMemberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheOneMember2022-09-300000805928us-gaap:MeasurementInputExpectedTermMemberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheOneMember2021-12-310000805928srt:MinimumMemberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheOneMemberaxgn:MeasurementInputCouponRateMember2022-09-300000805928srt:MaximumMemberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheOneMemberaxgn:MeasurementInputCouponRateMember2022-09-300000805928axgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheOneMemberaxgn:MeasurementInputCouponRateMember2021-12-310000805928axgn:DebtDerivativeLiabilityMemberus-gaap:MeasurementInputDiscountRateMemberaxgn:OberlandFacilityTrancheOneMember2022-09-300000805928axgn:DebtDerivativeLiabilityMemberus-gaap:MeasurementInputDiscountRateMemberaxgn:OberlandFacilityTrancheOneMember2021-12-310000805928axgn:MeasurementInputMandatoryPrepaymentRateMemberaxgn:MandatoryPrepaymentEventBefore2024Memberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheOneMember2022-09-300000805928axgn:MeasurementInputMandatoryPrepaymentRateMemberaxgn:MandatoryPrepaymentEventBefore2024Memberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheOneMember2021-12-310000805928axgn:MandatoryPrepaymentEventIn2024OrAfterMemberaxgn:MeasurementInputMandatoryPrepaymentRateMemberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheOneMember2022-09-300000805928axgn:MandatoryPrepaymentEventIn2024OrAfterMemberaxgn:MeasurementInputMandatoryPrepaymentRateMemberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheOneMember2021-12-310000805928axgn:MeasurementInputMandatoryPrepaymentRateMemberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheOneMemberaxgn:OptionalPrepaymentEventMember2022-09-300000805928axgn:MeasurementInputMandatoryPrepaymentRateMemberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheOneMemberaxgn:OptionalPrepaymentEventMember2021-12-310000805928us-gaap:MeasurementInputExpectedTermMemberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheTwoMember2022-09-300000805928us-gaap:MeasurementInputExpectedTermMemberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheTwoMember2021-12-310000805928axgn:DebtDerivativeLiabilityMemberaxgn:MeasurementInputCouponRateMemberaxgn:OberlandFacilityTrancheTwoMember2021-12-310000805928axgn:DebtDerivativeLiabilityMemberus-gaap:MeasurementInputDiscountRateMemberaxgn:OberlandFacilityTrancheTwoMember2022-09-300000805928axgn:DebtDerivativeLiabilityMemberus-gaap:MeasurementInputDiscountRateMemberaxgn:OberlandFacilityTrancheTwoMember2021-12-310000805928axgn:MeasurementInputMandatoryPrepaymentRateMemberaxgn:MandatoryPrepaymentEventBefore2024Memberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheTwoMember2022-09-300000805928axgn:MeasurementInputMandatoryPrepaymentRateMemberaxgn:MandatoryPrepaymentEventBefore2024Memberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheTwoMember2021-12-310000805928axgn:MandatoryPrepaymentEventIn2024OrAfterMemberaxgn:MeasurementInputMandatoryPrepaymentRateMemberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheTwoMember2022-09-300000805928axgn:MandatoryPrepaymentEventIn2024OrAfterMemberaxgn:MeasurementInputMandatoryPrepaymentRateMemberaxgn:DebtDerivativeLiabilityMemberaxgn:OberlandFacilityTrancheTwoMember2021-12-310000805928axgn:MeasurementInputMandatoryPrepaymentRateMemberaxgn:DebtDerivativeLiabilityMemberaxgn:OptionalPrepaymentEventMemberaxgn:OberlandFacilityTrancheTwoMember2022-09-300000805928axgn:MeasurementInputMandatoryPrepaymentRateMemberaxgn:DebtDerivativeLiabilityMemberaxgn:OptionalPrepaymentEventMemberaxgn:OberlandFacilityTrancheTwoMember2021-12-310000805928us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:FairValueInputsLevel1Memberaxgn:DebtDerivativeLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:FairValueInputsLevel2Memberaxgn:DebtDerivativeLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:FairValueInputsLevel3Memberaxgn:DebtDerivativeLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928axgn:DebtDerivativeLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000805928us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:FairValueInputsLevel1Memberaxgn:DebtDerivativeLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:FairValueInputsLevel2Memberaxgn:DebtDerivativeLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:FairValueInputsLevel3Memberaxgn:DebtDerivativeLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928axgn:DebtDerivativeLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000805928us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300000805928us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-07-012022-09-300000805928us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-01-012022-09-300000805928us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300000805928us-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-07-012021-09-300000805928us-gaap:FairValueInputsLevel3Memberaxgn:DebtDerivativeLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2021-07-012021-09-300000805928us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300000805928us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000805928us-gaap:LongTermDebtMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-09-300000805928us-gaap:FairValueInputsLevel3Memberaxgn:DebtDerivativeLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2021-01-012021-09-300000805928axgn:OberlandFacilityMember2022-09-300000805928axgn:OberlandFacilityMember2021-12-310000805928axgn:CommercialLeaseWithJAColeLPMember2022-01-272022-01-270000805928axgn:CommercialLeaseWithJAColeLPMember2022-01-270000805928axgn:CommercialLeaseWithJAColeLPFirstAmendmentMember2022-08-22utr:sqft0000805928axgn:CommercialLeaseWithJAColeLPMember2022-08-220000805928axgn:CommercialLeaseWithJAColeLPFirstAmendmentMember2022-08-222022-08-220000805928axgn:OberlandFacilityTrancheOneMember2022-09-300000805928axgn:OberlandFacilityTrancheOneMember2021-12-310000805928axgn:OberlandFacilityTrancheTwoMember2022-09-300000805928axgn:OberlandFacilityTrancheTwoMember2021-12-310000805928axgn:OberlandFacilityMember2020-06-302020-06-300000805928axgn:OberlandFacilityTrancheOneMember2020-06-300000805928axgn:OberlandFacilityTrancheTwoMember2021-06-300000805928axgn:OberlandFacilityMember2020-06-300000805928us-gaap:LondonInterbankOfferedRateLIBORMemberaxgn:OberlandFacilityMember2020-06-302020-06-300000805928axgn:OberlandFacilityMember2022-07-012022-09-300000805928axgn:OberlandFacilityMember2021-07-012021-09-300000805928axgn:OberlandFacilityMember2022-01-012022-09-300000805928axgn:OberlandFacilityMember2021-01-012021-09-300000805928axgn:DebtDerivativeLiabilityMember2022-09-300000805928axgn:DebtDerivativeLiabilityMember2021-12-31axgn:plan0000805928axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember2022-09-300000805928us-gaap:EmployeeStockOptionMember2021-12-310000805928us-gaap:EmployeeStockOptionMember2021-01-012021-12-310000805928us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000805928us-gaap:EmployeeStockOptionMember2022-09-300000805928axgn:RestrictedAndPerformanceStockUnitsMember2021-12-310000805928axgn:RestrictedAndPerformanceStockUnitsMember2021-01-012021-12-310000805928axgn:RestrictedAndPerformanceStockUnitsMember2022-01-012022-09-300000805928axgn:RestrictedAndPerformanceStockUnitsMember2022-09-300000805928us-gaap:PerformanceSharesMember2022-09-300000805928us-gaap:PerformanceSharesMemberaxgn:TwoThousandTwentyTwoMember2022-03-160000805928us-gaap:PerformanceSharesMemberaxgn:TwoThousandTwentyTwoMembersrt:MinimumMember2022-03-162022-03-160000805928us-gaap:PerformanceSharesMemberaxgn:TwoThousandTwentyTwoMembersrt:MaximumMember2022-03-162022-03-160000805928axgn:Axogen2017EmployeeStockPurchasePlanMember2022-09-300000805928axgn:Axogen2017EmployeeStockPurchasePlanMember2022-01-012022-09-300000805928us-gaap:EmployeeStockOptionMember2022-07-012022-09-300000805928us-gaap:EmployeeStockOptionMember2021-07-012021-09-300000805928us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000805928us-gaap:EmployeeStockOptionMember2021-01-012021-09-300000805928us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300000805928us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300000805928us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300000805928us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300000805928axgn:CommunityTissuesServicesAgreementMemberus-gaap:CostOfSalesMember2022-07-012022-09-300000805928axgn:CommunityTissuesServicesAgreementMemberus-gaap:CostOfSalesMember2021-07-012021-09-300000805928axgn:CommunityTissuesServicesAgreementMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000805928axgn:CommunityTissuesServicesAgreementMemberus-gaap:CostOfSalesMember2021-01-012021-09-300000805928axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember2011-12-012011-12-310000805928axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember2022-07-012022-09-300000805928axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember2021-07-012021-09-300000805928axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember2022-01-012022-09-300000805928axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember2021-01-012021-09-30axgn:product0000805928axgn:APCFacilityMember2018-07-31utr:acre0000805928axgn:APCFacilityMember2018-07-312018-07-310000805928us-gaap:ConstructionInProgressMemberaxgn:DesignBuildAgreementMember2022-07-012022-09-300000805928us-gaap:ConstructionInProgressMemberaxgn:DesignBuildAgreementMember2022-01-012022-09-300000805928us-gaap:ConstructionInProgressMemberaxgn:DesignBuildAgreementMember2019-07-092022-09-300000805928us-gaap:ConstructionInProgressMemberaxgn:DesignBuildAgreementMember2022-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________ to______________
Commission file number: 001-36046
Axogen, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Minnesota
(State or other jurisdiction of
incorporation or organization)

13631 Progress Blvd., Suite 400 Alachua, FL
(Address of principal executive offices)
41-1301878
(I.R.S. Employer
Identification No.)

32615
(Zip Code)

386-462-6800
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.01 par valueAXGNThe Nasdaq Stock Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes    No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes   No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No 
As of November 1, 2022, the registrant had 42,286,590 shares of common stock outstanding.



Table of Contents
Condensed Consolidated Balance Sheet as of September 30, 2022 and December 31, 2021 (Unaudited)

1



Forward-Looking Statements

From time to time, in reports filed with the U.S. Securities and Exchange Commission (the “SEC”) (including this Quarterly Report on Form 10-Q), in press releases, and in other communications to shareholders or the investment community, Axogen, Inc. (including Axogen, Inc.’s wholly owned subsidiaries, Axogen Corporation, Axogen Processing Corporation and Axogen Europe GmbH, the “Company,” “Axogen,” “we,” “our,” or “us”) may provide forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, concerning possible or anticipated future results of operations or business developments. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which the Company is active, as well as its business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Actual results or event could differ materially from those described in any forward-looking statements as a result of various factors, including, without limitation,, the impact of the COVID-19 and any and all variants thereof on our business, including but not limited to global supply chain issues; hospital staffing challenges and its impact on our business; statements regarding our growth, our financial guidance and performance; product development; product potential; Axogen Processing Center renovation timing and expense; sales growth; product adoption; market awareness of our products; anticipated capital requirements, including the potential of future financings; data validation; expected clinical study enrollment, timing and outcomes; our visibility at and sponsorship of conferences and our educational events; regulatory process and approvals; and other factors, including legislative, regulatory, political, geopolitical and economic developments, including record inflation and global business disruption caused by Russia’s invasion of Ukraine and related sanctions, not within our control. The forward-looking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q should be evaluated together with the many risks and uncertainties that affect the Company’s business and its market, particularly those discussed in the risk factors and cautionary statements set forth in the Company’s filings with the SEC, including as described in “Risk Factors” included in Item 1A and "Risk Factor Summary" included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, the Company assumes no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or otherwise.


2


PART 1 — FINANCIAL INFORMATION
ITEM 1 — FINANCIAL STATEMENTS
Axogen, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(In Thousands, Except Share and Per Share Amounts)
September 30,
2022
December 31,
2021
Assets
Current assets:
Cash and cash equivalents$14,318 $32,756 
Restricted cash6,251 6,251 
Investments38,792 51,330 
Accounts receivable, net of allowance for doubtful accounts of $606 and $276, respectively
21,363 18,158 
Inventory19,116 16,693 
Prepaid expenses and other2,614 1,861 
Total current assets102,454 127,049 
Property and equipment, net74,867 62,923 
Operating lease right-of-use assets14,751 15,193 
Intangible assets, net3,448 2,859 
Total assets$195,520 $208,024 
Liabilities and shareholders’ equity
Current liabilities:
Accounts payable and accrued expenses$22,017 $22,459 
Current maturities of long-term lease obligations1,530 1,834 
Total current liabilities23,547 24,293 
Long-term debt, net of debt discount and financing fees45,487 44,821 
Long-term lease obligations20,634 20,798 
Debt derivative liabilities4,407 5,562 
Total liabilities94,075 95,474 
Commitments and contingencies - see Note 12
Shareholders’ equity:
Common stock, 0.01 par value per share; 100,000,000 shares authorized; 42,272,223 and 41,736,950 shares issued and outstanding
423 417 
Additional paid-in capital355,187 342,765 
Accumulated deficit(254,165)(230,632)
Total shareholders’ equity101,445 112,550 
Total liabilities and shareholders’ equity$195,520 $208,024 
See notes to condensed consolidated financial statements.



Axogen, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(In Thousands, Except Per Share Amounts)
Three Months EndedNine Months Ended
September 30,
2022
September 30,
2021
September 30,
2022
September 30,
2021
Revenues$36,959 $31,204 $102,420 $95,821 
Cost of goods sold6,176 5,239 18,006 17,503 
Gross profit30,783 25,965 84,414 78,318 
Costs and expenses:
Sales and marketing19,792 18,370 60,349 55,594 
Research and development7,050 6,404 20,347 17,875 
General and administrative8,796 7,880 27,817 24,912 
Total costs and expenses35,638 32,654 108,513 98,381 
Loss from operations(4,855)(6,689)(24,099)(20,063)
Other (expense) income:
Investment income186 17 172 80 
Interest expense(61)(417)(664)(1,427)
Change in fair value of derivatives469 (46)1,155 (152)
Other expense(57)(6)(97)(137)
Total other expense, net537 (452)566 (1,636)
Net loss$(4,318)$(7,141)$(23,533)$(21,699)
Weighted average common shares outstanding — basic and diluted42,220,519 41,467,596 42,008,013 41,087,568 
Loss per common share — basic and diluted$(0.10)$(0.17)$(0.56)$(0.53)
See notes to condensed consolidated financial statements.



Axogen, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(In Thousands)
Nine Months Ended
September 30,
2022
September 30,
2021
Cash flows from operating activities:
Net loss$(23,533)$(21,699)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization2,182 2,059 
Amortization of right-of-use assets1,303 1,418 
Amortization of intangible assets198 148 
Amortization of debt discount and deferred financing fees667 384 
Provision for bad debt566 (145)
Provision for inventory write-down1,381 2,850 
Change in fair value of derivatives(1,155)152 
Investment losses44 49 
Stock-based compensation11,437 9,410 
Change in operating assets and liabilities:
Accounts receivable(3,695)(804)
Inventory(3,804)(5,774)
Prepaid expenses and other(828)1,146 
Accounts payable and accrued expenses(870)(927)
Operating lease obligations(1,320)(154)
Cash paid for interest portion of finance leases(1)(1)
Contract and other liabilities (3)
Net cash used in operating activities(17,428)(11,891)
Cash flows from investing activities:
Purchase of property and equipment(13,456)(20,641)
Economic development grant proceeds 950 
Purchase of investments(24,607)(39,139)
Proceeds from sale of investments37,100 49,300 
Cash payments for intangible assets(1,028)(534)
Net cash used in investing activities(1,991)(10,064)
Cash flows from financing activities:
Proceeds from the issuance of long-term debt 15,000 
Cash paid for debt portion of finance leases(9)(12)
Proceeds from exercise of stock options and ESPP stock purchases990 4,421 
Net cash provided by financing activities981 19,409 
Net decrease in cash, cash equivalents, and restricted cash(18,438)(2,546)
Cash, cash equivalents, and restricted cash, beginning of period39,007 55,609 
Cash, cash equivalents, and restricted cash, end of period$20,569 $53,063 
Supplemental disclosures of cash flow activity:
Cash paid for interest, net of capitalized interest$ $646 
Supplemental disclosure of non-cash investing and financing activities:
Acquisition of fixed assets in accounts payable and accrued expenses$2,090 $1,460 
Obtaining a right-of-use asset in exchange for a lease liability$920 $1,375 
Obtaining of property and equipment in exchange for a lease liability$22 $ 
Embedded derivative associated with the long-term debt$ $1,173 
Acquisition of intangible assets in accounts payable and accrued expenses$177 $261 
See notes to condensed consolidated financial statements.




Axogen, Inc.
Condensed Consolidated Statements of Changes in Shareholders’ Equity
(unaudited)
(In Thousands, Except Share Amounts)
Common StockAdditional Paid-in
Capital
Accumulated
Deficit
Total Shareholders'
Equity
SharesAmount
Three Months Ended September 30, 2022
Balance at June 30, 202242,134,504 $420 $351,117 $(249,847)$101,690 
Net loss— — — (4,318)(4,318)
Stock-based compensation— — 3,849 — 3,849 
Issuance of restricted and performance stock units55,934 1 (1)—  
Exercise of stock options and employee stock purchase plan81,785 2 222 — 224 
Balance at September 30, 202242,272,223 $423 $355,187 $(254,165)$101,445 
Nine Months Ended September 30, 2022
Balance at December 31, 202141,736,950 417 $342,765 $(230,632)$112,550 
Net loss— — — (23,533)(23,533)
Stock-based compensation— — 11,437 — 11,437 
Issuance of restricted and performance stock units315,275 3 (3)—  
Exercise of stock options and employee stock purchase plan219,998 3 988 — 991 
Balance at September 30, 202242,272,223 $423 $355,187 $(254,165)$101,445 
Three Months Ended September 30, 2021
Balance at June 30, 202141,337,108 $413 $336,495 $(218,205)118,703 
Net loss— $— $— $(7,141)$(7,141)
Stock-based compensation— — 2,911 — 2,911 
Issuance of restricted and performance stock units67,249 $1 $(1)$— $ 
Exercise of stock options and employee stock purchase plan154,572 1 807 — 808 
Balance at September 30, 202141,558,929 $415 $340,212 $(225,346)$115,281 
Nine Months Ended September 30, 2021
Balance at December 31, 202040,618,766 $406 $326,390 $(203,647)123,149 
Net loss— — — (21,699)(21,699)
Stock-based compensation— — 9,410 — 9,410 
Issuance of restricted and performance stock units206,193 2 (2)—  
Exercise of stock options and employee stock purchase plan733,970 7 4,414 — 4,421 
Balance at September 30, 202141,558,929 $415 $340,212 $(225,346)$115,281 
See notes to condensed consolidated financial statements.



Axogen, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(In Thousands, Except Per Share Amounts)

1.Basis of Presentation
General
Unless the context otherwise requires, all references in these Notes to “Axogen,” the “Company,” “we,” “us” and “our” refer to Axogen, Inc. and its wholly owned subsidiaries Axogen Corporation (“AC”), Axogen Processing Corporation, and Axogen Europe GmbH.
The accompanying unaudited condensed consolidated financial statements include the accounts of the Company as of September 30, 2022, and December 31, 2021, and for the three and nine months ended September 30, 2022, and 2021. The Company’s condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X, and; therefore, do not include all information and footnotes necessary for a fair presentation of consolidated financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2021, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of results for the periods presented. Results for interim periods are not necessarily indicative of results for the full year. All intercompany accounts and transactions have been eliminated in consolidation.
The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the results to be expected for the full year due primarily to the impact of the continued uncertainty of general economic conditions that may impact our markets for the remainder of fiscal year 2022. Specifically, there can be no assurance that the resurgence of COVID-19 will not affect future results.
Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
2.Summary of Significant Accounting Policies

Please see Note 2 to the Company’s consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on February 28, 2022 for a description of all significant accounting policies.
Cash and Cash Equivalents and Concentration
The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying condensed consolidated financial statements. The Company has not experienced any losses related to these balances; however, as of September 30, 2022, $13,818 of the cash and cash equivalents balance was in excess of Federal Deposit Insurance Corporation limits. The Company had restricted cash balances of $6,251 for each of the periods ended September 30, 2022, and December 31, 2021. The September 30, 2022, and December 31, 2021, balances both include $6,000 and $250, which represent collateral for two irrevocable standby letters of credit. See "Note 8 - Long-Term Debt, Net of Debt Discount and Financing Fees."



The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:
(In thousands)September 30,
2022
December 31,
2021
Cash and cash equivalents$14,318 $32,756 
Restricted cash6,251 6,251 
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows$20,569 $39,007 
Stock-Based Compensation
The Company measures stock options granted to employees at a premium price based on market conditions, such as the trading price of the Company’s common stock, using a Monte Carlo Simulation model in estimating the fair value at grant date. The determination of the fair value is affected by the Company's stock price, as well as assumptions regarding several subjective variables. These variables include, but are not limited to, the Company’s expected stock price volatility over the term of the awards. The Company determines the expected life of each award giving consideration to the contractual terms, vesting schedules, and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The expense has been reduced for forfeitures as they occur.
The Company recognizes expense for all stock-based compensation awards, including stock options, restricted stock units ("RSUs"), and performance stock units ("PSUs") granted to employees eligible for retirement, as defined within the award notice and allowing for continued vesting post-retirement, over the retirement notice period and continuously updates its estimate of expense over the notice period each reporting period if a retirement notice has not been provided.
Costs of Goods Sold
Cost of sales includes direct labor and materials costs related to each product sold or produced, including processing, quality assurance labor and scrap, as well as facility and warehousing overhead supporting our manufacturing operations. All of our manufacturing costs are included in cost of sales.
Shipping and Handling
All shipping and handling costs, including facility and warehousing overhead, directly related to bringing the Company’s products to their final selling destination are in included in selling and marketing expenses. Shipping and handling costs included in sales and marketing were $1,330 and $1,366 for the three months ended September 30, 2022, and 2021, respectively and $3,863 and $3,657 for the nine months ended September 30, 2022, and 2021, respectively.
Recent Accounting Pronouncements
In November 2021, the Financial Accounting Standards ("FASB") amended Accounting Standards Codification ("ASC") 832, Government Assistance (issued under Accounting Standards Update ("ASU") 2021-10, Disclosures by Business Entities about Government Assistance). This amendment requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy, including, (1) the types of transactions; (2) the financial statement line items affected by the transaction, and; (3) significant terms and conditions associated with the transactions. The Company adopted the guidance on January 1, 2022 and the adoption of ASU 2021-10 did not to have a material impact on the Company's condensed consolidated financial condition, results of operations or disclosures.



3.     Inventory
Inventory consisted of the following (in thousands):
September 30,
2022
December 31,
2021
Finished goods$12,823 $11,011 
Work in process903 813 
Raw materials5,390 4,869 
Inventory$19,116 $16,693 
The provision for inventory write-down was $452 and $395 for the three months ended September 30, 2022, and 2021, respectively, and for the nine months ended September 30, 2022, and 2021, the Company had adjustments to the provision for inventory write-downs of $1,381 and $2,850 (including the write-down of Avive inventory of $1,251 in the 2021 period), respectively.



4.     Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
September 30,
2022
December 31,
2021
Furniture and equipment$5,408 $5,100 
Leasehold improvements15,569 14,952 
Processing equipment4,229 3,984 
Land731 731 
Projects in process58,595 45,660 
Finance lease right-of-use assets131 110 
Property and equipment, at cost84,663 70,537 
Less: accumulated depreciation and amortization(9,796)(7,614)
Property and equipment, net$74,867 $62,923 
The Company further added to its projects in process total which is related to our Axogen Processing Center (“APC Facility”). See "Note 12 - Commitments and Contingencies."
Depreciation expense consisted of following (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Depreciation expense$764 $654 $2,182 $2,059 
Depreciation expense is allocated among cost of sales, sales and marketing, research and development, and general and administrative expense on the condensed consolidated statements of operations.
5.     Intangible Assets, Net
The Company’s intangible assets consisted of the following (in thousands):
September 30, 2022December 31, 2021
Gross Carrying AmountAccumulated AmortizationNet Carrying AmountGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Amortizable intangible assets:
Patents$3,245 $(342)$2,903 $2,469 $(234)$2,235 
License agreements1,101 (943)158 1,101 (852)249 
Total amortizable intangible assets4,346 (1,285)3,061 3,570 (1,086)2,484 
Unamortized intangible assets
Trademarks387 — 387 375 — 375 
Total intangible assets$4,733 $(1,285)$3,448 $3,945 $(1,086)$2,859 
Amortization expense consisted of the following (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Amortization expense$66 $52 $198 $148 




Expected future amortization of intangible assets as of September 30, 2022, is as follows (in thousands):
Year Ending December 31,Expected Amortization Expense
2022 (excluding the nine months ended September 30, 2022)$68 
2023237 
2024169 
2025169 
2026167 
Thereafter2,251 
Total amortized intangible assets$3,061 

License Agreements
The Company has License Agreements with the University of Florida Research Foundation and the University of Texas at Austin in which certain royalty payments are paid quarterly.
Royalty expense consisted of the following (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Royalty expense$848 $687 $2,287 $2,037 
Royalty fees are included in sales and marketing expense on the accompanying condensed consolidated statements of operations.
6.     Fair Value Measurement
Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for classification and disclosure of fair value measurements as follows:
Level 1 – Quoted prices in active markets for identical assets or liabilities.
Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
There has been no movement between Level 1 and Level 2 or between Level 2 and Level 3 from December 31, 2021, to September 30, 2022. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
Debt Derivative Liabilities
The Debt Derivative Liabilities are measured using a ‘with and without’ valuation model to compare the fair value of the Company's financing agreement with Oberland Capital including the identified embedded derivative features and the fair value of a plain vanilla note with the same terms. The fair value of the Oberland Facility including the embedded derivative features was determined using a probability-weighted expected return model based on four potential settlement scenarios for the Oberland Facility due to (a) a 5% probability of a mandatory prepayment event of the Oberland Facility on December 31, 2023; (b) a 15% probability of a mandatory prepayment event of the Oberland Facility on March 31, 2026; (c) a 5% probability of the prepayment of the Oberland Facility at the Company’s option on December 31, 2025; and (d) a 75% probability that the Oberland Facility will be held to its scheduled maturity dates in accordance with the terms of the debt agreement. The estimated settlement value of each scenario, which would include any required make-whole payment, is then discounted to present value



using a discount rate that is derived based on the initial terms of the Oberland Facility at issuance and corroborated utilizing a synthetic credit rating analysis.
The significant inputs that are included in the valuation of the Debt derivative liability - first tranche include:
September 30, 2022December 31, 2021
Input
Remaining term (years)4.75 years5.5 years
Maturity dateJune 30, 2027June 30, 2027
Coupon rate
9.5% - 12.3%
9.5 %
Revenue participation paymentsMaximum each yearMaximum each year
Discount rate14.7(1)10.72(1)
Probability of mandatory prepayment before 20245.0 %(1)5.0 %(1)
Estimated timing of mandatory prepayment event before 2024December 31, 2023(1)December 31, 2023(1)
Probability of mandatory prepayment 2024 or after15.0 %(1)15.0 %(1)
Estimated timing of mandatory prepayment event 2024 or afterMarch 31, 2026(1)March 31, 2026(1)
Probability of optional prepayment event5.0 %(1)5.0 %(1)
Estimated timing of optional prepayment eventDecember 31, 2025(1)December 31, 2025(1)
(1)Represents a significant unobservable input
The significant inputs that are included in the valuation of the Debt derivative liability - second tranche include:
September 30, 2022December 31, 2021
Input
Remaining term (years)5.75 years6.5
Maturity dateJune 30, 2028June 30, 2028
Coupon rate
9.5% - 12.3%
9.5
Revenue participation paymentsMaximum each yearMaximum each year
Discount rate18.3 %(1)13.21 %(1)
Probability of mandatory prepayment before 20245.0(1)5.0(1)
Estimated timing of mandatory prepayment event before 2024December 31, 2023(1)December 31, 2023(1)
Probability of mandatory prepayment 2024 or after15.0(1)15.0(1)
Estimated timing of mandatory prepayment event 2024 or afterMarch 31, 2026(1)March 31, 2026(1)
Probability of optional prepayment event5.0(1)5.0(1)
Estimated timing of optional prepayment eventDecember 31, 2025(1)December 31, 2025(1)
(1)Represents a significant unobservable input



The following table presents the financial assets and liabilities that the Company measured at fair value on a recurring basis as of September 30, 2022, classified in accordance with the fair value hierarchy (in thousands):
Fair Value Measurements Using
(Level 1)(Level 2)(Level 3)Total
Assets:
Money market funds$7,610 $ $ $7,610 
U.S. government securities22,874   22,874 
Commercial paper 15,918  15,918 
Total assets$30,484 $15,918 $ $46,402 
Liabilities
Debt derivative liabilities  4,407 4,407 
Total liabilities$ $ $4,407 $4,407 
The following table presents the financial assets and liabilities that the Company measured at fair value on a recurring basis as of December 31, 2021, classified in accordance with the fair value hierarchy (in thousands):
Fair Value Measurements Using
(Level 1)(Level 2)(Level 3)Total
Assets:
Money market funds$22,012 $ $ $22,012 
U.S. government securities12,081   12,081 
Commercial paper 39,249  39,249 
Total assets$34,093 $39,249 $ $73,342 
Liabilities
Debt derivative liabilities$ $5,562 $5,562 
Total liabilities$ $ $5,562 $5,562 
The changes in Level 3 liabilities measured at fair value on a recurring basis for the three and nine months ended September 30, 2022, were as follows (in thousands):
Three Months Ended September 30, 2022
Beginning Balance, July 1, 2022$4,876 
Change in fair value included in net loss(469)
Ending Balance, September 30, 2022$4,407 
Nine Months Ended September 30, 2022
Beginning Balance, January 1, 2022$5,562 
Change in fair value included in net loss(1,155)
Ending Balance, September 30, 2022$4,407 



The changes in Level 3 liabilities measured at fair value on a recurring basis for the three and nine months ended September 30, 2021, were as follows (in thousands):
Three Months Ended September 30, 2021
Beginning Balance, July 1, 202154,439 
Change in fair value of Oberland Facility(826)
Change in fair value of debt derivative46 
Ending Balance, September 30, 2021$53,659 
Nine Months Ended September 30, 2021
Beginning Balance, January 1, 2021$39,352 
Addition of Oberland Facility - second tranche13,827 
Addition of debt derivative - second tranche1,173 
Change in fair value of Oberland Facility(845)
Change in fair value of debt derivative152 
Ending Balance September 30, 2021$53,659 
The fair value of cash, restricted cash, accounts receivable, accounts payable and accrued expenses approximate the carrying values because of the short-term nature of these instruments. The Oberland Facility is classified as Level 3 within the fair value hierarchy. The carrying value and estimated fair value of the Oberland Facility were $45,487 and $49,392 at September 30, 2022, and $45,325 and $52,605 at December 31, 2021, respectively. See "Note 8 - Long-Term Debt, Net of Debt Discount and Financing Fees."




7.     Leases
The Company leases administrative, manufacturing, research and distribution facilities through operating leases. Several leases include fixed payments including rent and non-lease components such as common-area or other maintenance costs.
On January 27, 2022, the Company entered into a Commercial Lease Amendment ("Amendment") with JA-Cole L.P., with an effective date of February 1, 2022, pursuant to the original Commercial Lease dated April 21, 2015, as amended (the "Lease"). The lease is for the office and warehouse facility located in Burleson, Texas. The Amendment revised the commencement date to May 1, 2022, and the expiration date to April 30, 2027. The Company accounted for the Lease revisions as a lease modification in accordance with ASC 842, Leases, as the modification effectively terminated the existing lease and created a new lease which commenced on February 1, 2022. The Company valued the lease using a 11.3% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $641 as a result of this amendment.
On August 22, 2022, the Company, entered into the First Amendment to Lease Agreement (the “First Amendment”) with Ja-Cole, L.P. with an effective date of October 1, 2022, pursuant to the original Commercial Lease dated October 1, 2020, as amended (the "Lease"). The lease is for the office and warehouse facility located in Burleson, Texas. The First Amendment adds an additional 2,500 square feet to the Leased Premises, for a total of 5,000 square feet and revises the expiration date of the Lease to mean September 30, 2027. The Company accounted for the Lease revisions as a lease modification in accordance with ASC 842, Leases, as the modification effectively terminated the existing lease and created a new lease. The Company valued the lease using a 12.8% incremental borrowing rate and recorded a right-of-use asset and a lease liability of 221 as a result of this amendment.
Total operating lease expense for the three months ended September 30, 2022, and 2021 was $1,337 and $1,211 respectively and $4,100 and $3,652 for the nine months ended September 30, 2022, and 2021, respectively.
Supplemental balance sheet information related to the operating and financing leases is as follows:
(In thousands, except lease term and discount rate)September 30, 2022December 31, 2021
Operating Leases
Right-of-use operating assets$14,751 $15,193 
Current maturities of long-term lease obligations$1,523 $1,825 
Long-term lease obligations$20,615 $20,794 
Financing Leases
Right-of-use financing leases (1)
$46 $42 
Current maturities of long-term lease obligations $7 $9 
Long-term lease obligations $19 $4 
Weighted average operating lease term (in years):10.912.1
Weighted average operating financing term (in years):4.22.2
Weighted average discount rate operating leases10.48 %10.32
Weighted average discount rate financing leases11.697.23
(1) Financing leases are included within property and equipment, net on the condensed consolidated balance sheets.



Future minimum lease payments under operating and financing leases at September 30, 2022, were as follows:
(In thousands) 
2022 (excluding the nine months ended September 30, 2022)$1,092 
20233,476 
20243,253 
20253,336 
20263,348 
20272,921 
Thereafter20,931 
Total$38,356 
Less: Imputed interest(16,192)
Total lease liability$22,164 
Less: Current lease liability (1,530)
Long-term lease liability$20,634 
8.     Long-Term Debt, Net of Debt Discount and Financing Fees
Long-term debt, net of debt discount and financing fees consists of the following:
(In thousands)September 30,
2022
December 31, 2021
Oberland Facility - first tranche$35,000 $35,000 
Oberland Facility - second tranche15,000 15,000 
Less - unamortized debt discount and deferred financing fees(4,513)(5,179)
Long-term debt, net of debt discount and financing fees$45,487 $44,821 
Oberland Facility
On June 30, 2020, the Company entered into a seven-year financing agreement with Oberland Capital (the "Oberland Facility") and obtained the first tranche of $35,000 at closing. On June 30, 2021, the second tranche of $15,000 was drawn down by the Company.
The Oberland Facility requires quarterly interest payments for seven years. Interest is calculated as 7.5% plus the greater of LIBOR or 2.0% (9.8% as of September 30, 2022). Each tranche of the Oberland Facility has a term of seven years from the date of issuance (with the first tranche issued on June 30, 2020, maturing on June 30, 2027 and the second tranche issued on June 30, 2021, maturing on June 30, 2028). In connection with the Oberland Facility, the Company entered into a revenue participation agreement with Oberland Capital, which provides that, among other things, a quarterly royalty payment as a percentage of the Company’s net revenues, up to $70 million in any given fiscal year, subject to certain limitations set forth therein, during the period commencing on the later of (i) April 1, 2021, and (ii) the date of funding of a tranche of the loan, and ending on the date upon which all amounts owed under the Oberland Facility have been paid in full (the “Revenue Participation Agreement”). Payments under the Revenue Participant Agreement commenced on September 30, 2021. The royalty structure of the Revenue Participant Agreement results in approximately 1.0% per year of additional interest payments on the outstanding loan amount. The Company recorded interest expense of $49 and $337 for this Revenue Participation Agreement for the three months ended September 30, 2022, and 2021 and $756 and $590 for the nine months ended September 30, 2022 and 2021, respectively. The Company exceeded the maximum annual revenue participation threshold of $70,000 during the third quarter of 2022. The Company pays Oberland Capital quarterly debt interest on the last day of the quarter. The Company paid $1,249 and $1,218 for the three months ended September 30, 2022, and 2021, respectively, and $3,637 and $2,890 for the nine months ended September 30, 2022, and 2021, respectively. The Company capitalized interest of $1,450 and $1,338 for the three months ended September 30, 2022 and 2021, respectively and $4,474 and $2,526 for the nine months ended September 30, 2022 and 2021, respectively, towards the costs to construct and retrofit the APC Facility in Vandalia, OH. See "Note 12 - Commitments and Contingencies." Since inception, the Company has capitalized interest of $9,748 related to this project. The capitalized interest is recorded as part of property and equipment, net in the condensed consolidated balance sheets. As of September 30, 2022, the Company was in compliance with all financial covenants. See "Note 12 - Commitments and Contingencies."



Embedded Derivatives
The Debt Derivative Liabilities are recorded at fair value, with the change in fair value reported in the condensed consolidated statements of operations at each reporting date. The fair values of the Debt Derivative Liabilities were $4,407 and $5,562 at September 30, 2022, and December 31, 2021, respectively. See "Note 6 - Fair Value Measurement."
Unamortized Debt Discount and Financing Fees
The unamortized debt discount consists of the remaining unamortized initial fair values of the embedded derivatives related to the first and second tranches of the Oberland Facility. The debt discount is amortized over the respective life of the related tranche and recorded in interest expense using the effective yield method.
The financing fees for the Oberland Facility were $642 and were recorded as a contra liability to the debt facility. The financing fees are amortized over the life of the first tranche of the Oberland Facility and recorded in interest expense.
Amortization of debt discount and deferred financing fees for the three months ended September 30, 2022, and 2021 was $225 and $157, respectively, and for the nine months ended September 30, 2022, and 2021 was $667 and $384, respectively.
Other credit facilities
The Company had restricted cash of $6,251 at September 30, 2022, and December 31, 2021. The September 30, 2022, and December 31, 2021, balances both include $6,000 and $250, which represent collateral for two irrevocable standby letters of credit.

9.     Stock-Based Incentive Plans
The Company maintains two share-based incentive plans: the Axogen, Inc. Second Amended and Restated 2019 Long-Term Incentive Plan, (“2019 Plan”), and the Axogen 2017 Employee Stock Purchase Plan (“2017 ESPP”). As of September 30, 2022, 3,340,010 shares of common stock were available for issuance under the 2019 Plan. The Company recognized share-based compensation expense, which consisted of compensation expense related to stock options, PSUs and RSUs based on the value of share-based payment awards that are ultimately expected to vest during the period and stock-based compensation expense of $3,849 and $2,911 for the three months ended September 30, 2022 and 2021, respectively, and $11,437 and $9,410 for the nine months ended September 30, 2022, and 2021, respectively.
A summary of the stock option activity is as follows:
OptionsWeighted Average Exercise PriceWeighted Average Remaining Contractual LifeAggregate Intrinsic Value (in thousands)
Outstanding, December 31, 20213,194,738 $15.65 6.45$2,236 
Granted1,185,749 $9.13 
Exercised(153,290)$4.44 
Cancelled(229,964)$14.83 
Outstanding, September 30, 20223,997,233 $14.20 6.77$7,772 
Exercisable, September 30, 20222,117,574 $15.63 4.85$4,059 



The Company used the following weighted-average assumptions for options granted during the nine months ended September 30, 2022:
Expected term (in years)6.02
Expected volatility61.06  %
Risk free rate2.26  %
Expected dividends  %
As of September 30, 2022, there was approximately $8,251 of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of 2.6 years.
Restricted and Performance Stock Units
A summary of the restricted and performance stock unit activity is as follows:
Outstanding Stock Units
Stock UnitsWeighted-Average Fair Value at Date of Grant per ShareWeighted Average Remaining Vesting LifeAggregate Intrinsic Value (in thousands)
Unvested, December 31, 20211,730,765 $18.45 1.51$19,633 
Granted1,916,963 $8.31 
Released(315,275)$14.12 
Forfeited(331,260)$13.42 
Unvested, September 30, 20223,001,193 $12.98 1.82$35,774 
Performance Stock Units
At September 30, 2022, the total future stock compensation expense related to non-vested performance awards at maximum target payout is expected to be approximately $3,774. As of September 30, 2022, there was approximately $17,487 of total unrecognized compensation costs related to both the PSU and RSU unvested awards. The Company expects to recognize these costs over a weighted-average period of 2.8 years.
On March 16, 2022, the Compensation Committee of the Board of Directors approved PSUs that were tied to 2022, 2023 and 2024 revenue (the “2022 PSU award.”) The 2022 PSU award consists of a targeted award of 526,467 shares with a payout ranging from 0% to 150% upon achievement of specific revenue goals.
Employee Stock Purchase Plan
The Company also maintains the 2017 ESPP, which allows eligible employees to acquire shares of the Company’s common stock through payroll deductions at a discount to market price. A total of 600,000 shares of the Company’s common stock are authorized for issuance under the 2017 ESPP, and as of September 30, 2022, 126,674 shares remain available for issuance.
10.     Net Loss Per Common Share
The following reflects the net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two-class method:



Three Months Ended September 30,Nine Months Ended September 30,
(In thousands, except per share amounts)2022202120222021
Numerator:
Net loss $(4,318)$(7,141)$(23,533)$(21,699)
Denominator:
Weighted-average common shares outstanding (Basic)42,220,519 41,467,596 42,008,013 41,087,568 
Weighted-average common shares outstanding (Diluted)42,220,519 41,467,596 42,008,013 41,087,568 
Net loss per common share (Basic and Diluted)$(